Roivant Acquires Mosliciguat from Bayer for Pulmonary Hypertension Treatment
核心洞察
Roivant Sciences (搜索) has acquired mosliciguat, an experimental drug, from Bayer to develop as a treatment for pulmonary hypertension (搜索).
Mosliciguat targets specific types of pulmonary hypertension (搜索), addressing high blood pressure in lung arteries and heart damage.
This acquisition expands Roivant's pipeline in pulmonary disease and represents Bayer's strategic divestment of the drug.
Roivant Sciences (搜索) has acquired mosliciguat, an experimental drug, from Bayer, aiming to develop it as a treatment for specific types of pulmonary hypertension (搜索). Pulmonary hypertension is a serious condition characterized by high blood pressure in the arteries of the lungs, leading to damage to the heart.
Acquisition Details
The acquisition allows Roivant to expand its pipeline in pulmonary disease. Mosliciguat, the drug acquired, is an experimental therapy that Bayer was developing. The financial terms of the deal were not disclosed.
About Mosliciguat
Mosliciguat is intended to treat pulmonary hypertension (搜索), a condition where high blood pressure in the lung arteries causes damage to the heart. The drug has undergone some initial development by Bayer, and Roivant plans to continue its development for specific subtypes of pulmonary hypertension. Further details on the mechanism of action and previous trial data were not disclosed in the announcement.